Gastric CancerStomachCancerNCT07528131
18F-FDG PET/CT in Gastric Cancer
An observational study of Gastric Cancer, run by Sohag University at 1 site in Egypt.
Trial summary
PET and PET/CT imaging remains promising, and with current and further improvements, PET and PET/CT imaging may make the diagnosis and evaluation of gastric cancer more standardized and accurate. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gastric Cancer
- How many people
- 50 participants
- Where
- 1 siteEgypt
- Study dates
- 22 Sep 2023to 22 Sep 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The Current Retrospective and Prospective study was conducted among 50 histologically confirmed Gastric Cancer patients ,mean age of the studied cases was 57.58 ± 10.26 years and ranged between (35-77) years. Moreover, the study included 29 males (58%) and 21 females (42%).
Who may be able to join
- Patients diagnosed as Gastric Cancer on surgically resected specimens.
- Patients with gastric and extragastric metastasis.
- Patients with gastric cancer either operated or not
Who cannot join
- Patients with second malignancy (Double primary).
- Patient without proven pathology of Cancer Stomach.
- Severely ill patient (patient with disturbed conscious level, or couldn't lay supine during the imaging).
- Uncontrolled diabetic patient with blood glucose level more than 200mg\dl.
- Pregnant women.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Role of 18F-FDG in Gastric Cancer
PET and PET/CT imaging remains promising, and with current and further improvements, PET and PET/CT imaging may make the diagnosis and evaluation of gastric cancer more standardized and accurate.
Read the detailed description
This retrospective and prospective study was conducted to evaluate the effectiveness of 18 F-FDG PET/CT imaging in diagnosis of gastric cancer in correlation to other imaging modalities and clinical follow up.
This study included 50 patient pathologically proved gastric cancer. After obtaining written consent from the participants, detailed history was obtained from participants with the help of their data sheets, revision of pathology report (confirmed diagnosis of primary GC), the referral report from the treating physician and any imaging modalities patients were done, FDG PET/CT study was done using dedicated PET/CT scanner, and PET analysis was performed qualitatively and semi qualitatively, tissue biopsy was obtained from patients whenever it was possible.
Results of the current study demonstrate that FDG PET/CT was more accurate and more sensitive than CT in detection of occult distant metastases in advanced or equivocal cases, detection of metabolically active LNs that are morphologically normal on CT, helpful for recurrence detection, and informative for early metabolic response in FDG-avid tumors using standardized criteria (PERCIST),that may not be apparent using other modalities, and may have prognostic value that can change patient management.
PET/CT was more accurate than CT in Detection of Distant metastasis of gastric cancer (liver metastasis, lung metastasis, bone metastasis).
¹⁸F-FDG PET/CT is not a stand-alone staging tool for gastric cancer, but used selectively it meaningfully improves detection of distant metastasis, refines patient selection for radical treatment, and reduces futile surgery.
Clinicians must interpret PET/CT results in light of histologic subtype and complementary diagnostic procedures (endoscopy, laparoscopy, CT). Future work should validate FAPI tracers and define precise clinical pathways where PET/CT adds cost-effective benefit.
- Conditions
- Gastric Cancer
- Keywords
- FDGPET/Ct, SUVmax, Gastric Cancer,
- Medical subject headings
- Stomach Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
diagnosis ,staging ,assessment of treatment response and assessment of recurrence
assess the value of SUVmax in every detected lesion in relation to the liver uptake and compare if this lesion deteced in other investigation
Measured: 12months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2026
- Study start22 Sep 2023
- Primary completion22 Sep 2024
- Study completion22 Sep 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric CancerStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Other
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Collaborators
- Assiut University
- Responsible party
- Principal investigator, Sara Saber Ahmed, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07528131
- Sponsor's protocol ID
- stomach cancer
- Acronym
- StomachCancer
- Status last verified
- Apr 2026
- First submitted
- 7 Apr 2026
- Last updated
- 14 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: the individual participant data will not be made available to other researchers to maintain patient confidentiality.
Study at a glance
From the registry record, last updated by the sponsor on 14 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Role of 18F-FDG in Gastric Cancer
- ClinicalTrials.gov ID
- NCT07528131
- Acronym / sponsor ID
- StomachCancer / stomach cancer
- Conditions
- Gastric Cancer
- Keywords
- FDGPET/Ct, SUVmax, Gastric Cancer,
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Collaborators
- Assiut University
- Study start
- 22 Sep 2023 (actual)
- Primary completion
- 22 Sep 2024 (actual)
- Study completion
- 22 Sep 2024 (actual)
- First posted
- 14 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
PET and PET/CT imaging remains promising, and with current and further improvements, PET and PET/CT imaging may make the diagnosis and evaluation of gastric cancer more standardized and accurate.
Detailed description
This retrospective and prospective study was conducted to evaluate the effectiveness of 18 F-FDG PET/CT imaging in diagnosis of gastric cancer in correlation to other imaging modalities and clinical follow up.
This study included 50 patient pathologically proved gastric cancer. After obtaining written consent from the participants, detailed history was obtained from participants with the help of their data sheets, revision of pathology report (confirmed diagnosis of primary GC), the referral report from the treating physician and any imaging modalities patients were done, FDG PET/CT study was done using dedicated PET/CT scanner, and PET analysis was performed qualitatively and semi qualitatively, tissue biopsy was obtained from patients whenever it was possible.
Results of the current study demonstrate that FDG PET/CT was more accurate and more sensitive than CT in detection of occult distant metastases in advanced or equivocal cases, detection of metabolically active LNs that are morphologically normal on CT, helpful for recurrence detection, and informative for early metabolic response in FDG-avid tumors using standardized criteria (PERCIST),that may not be apparent using other modalities, and may have prognostic value that can change patient management.
PET/CT was more accurate than CT in Detection of Distant metastasis of gastric cancer (liver metastasis, lung metastasis, bone metastasis).
¹⁸F-FDG PET/CT is not a stand-alone staging tool for gastric cancer, but used selectively it meaningfully improves detection of distant metastasis, refines patient selection for radical treatment, and reduces futile surgery.
Clinicians must interpret PET/CT results in light of histologic subtype and complementary diagnostic procedures (endoscopy, laparoscopy, CT). Future work should validate FAPI tracers and define precise clinical pathways where PET/CT adds cost-effective benefit.
Study design
- Observational model
- Case only
- Time perspective
- Other
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The Current Retrospective and Prospective study was conducted among 50 histologically confirmed Gastric Cancer patients ,mean age of the studied cases was 57.58 ± 10.26 years and ranged between (35-77) years. Moreover, the study included 29 males (58%) and 21 females (42%).
Key inclusion criteria (3 listed)
- Patients diagnosed as Gastric Cancer on surgically resected specimens.
- Patients with gastric and extragastric metastasis.
- Patients with gastric cancer either operated or not
Key exclusion criteria (5 listed)
- Patients with second malignancy (Double primary).
- Patient without proven pathology of Cancer Stomach.
- Severely ill patient (patient with disturbed conscious level, or couldn't lay supine during the imaging).
- Uncontrolled diabetic patient with blood glucose level more than 200mg\dl.
- Pregnant women.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
diagnosis ,staging ,assessment of treatment response and assessment of recurrence
Time frame: 12months
assess the value of SUVmax in every detected lesion in relation to the liver uptake and compare if this lesion deteced in other investigation
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Apr 2026.
- Individual participant dataSharing planned: No. the individual participant data will not be made available to other researchers to maintain patient confidentiality.
Related trials for Gastric Cancer
RecruitingPhase 2/3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Recruiting
Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial
Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
RecruitingPhase 2
Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Stomach Neoplasms
Active, not recruiting
Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery
Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma
Active, not recruitingPhase 2
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastric Cancer, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
diagnosis ,staging ,assessment of treatment response and assessment of recurrence (time frame: 12months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2026.